Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCytomX Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.15 | -$0.02 | -$0.10 |
| Q2 2025 | 1 | -$0.20 | -$0.05 | -$0.12 |
| Q3 2025 | 1 | -$0.14 | -$0.03 | -$0.08 |
| Q4 2025 | 1 | -$0.28 | -$0.06 | -$0.16 |
| Q1 2026 | 1 | -$0.40 | -$0.09 | -$0.23 |
| Q2 2026 | 1 | -$0.40 | -$0.09 | -$0.23 |
| Q3 2026 | 1 | -$0.41 | -$0.09 | -$0.24 |
| Q4 2026 | 1 | -$0.42 | -$0.10 | -$0.24 |
CytomX Therapeutics, Inc. Earnings Date And Information
CytomX Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of $-0.17 by $0.24. The company had revenue of 33.43 M for the quarter and had revenue of 101.21 M for the year. CytomX Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.0077 diluted earnings per share) and currently has a price-to-earnings ratio of 6.58. CytomX Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based on prior year's report dates.
CytomX Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.17 | $0.07 | 0.24 | $17.10 M | $33.43 M |
| 08/08/2024 | Q2 2024 | -$0.07 | -$0.08 | -0.01 | $20.00 M | $25.12 M |
| 05/08/2024 | Q1 2024 | $0.17 | $41.46 M | |||
| 03/11/2024 | Q4 2023 | $0.00 | $0.01 | 0.01 | $26.61 M | |
| 11/07/2023 | Q3 2023 | -$0.19 | $0.04 | 0.23 | $13.34 M | $26.38 M |
| 08/08/2023 | Q2 2023 | -$0.19 | -$0.02 | 0.17 | $13.68 M | $24.72 M |
| 05/09/2023 | Q1 2023 | -$0.16 | -$0.01 | 0.15 | $23.50 M | |
| 03/27/2023 | Q4 2022 | -$0.21 | -$0.40 | -0.19 | $946,000 | |
| 11/08/2022 | Q3 2022 | -$0.32 | -$0.34 | -0.02 | $18.15 M | $16.92 M |
| 08/04/2022 | Q2 2022 | -$0.36 | -$0.36 | 0 | $18.11 M | $18.17 M |
| 05/05/2022 | Q1 2022 | -$0.35 | -$0.36 | -0.01 | $17.14 M | |
| 03/01/2022 | Q4 2021 | -$0.25 | -$0.40 | -0.15 | $19.73 M | |
| 11/04/2021 | Q3 2021 | -$0.30 | -$0.35 | -0.05 | $18.38 M | $17.59 M |
| 08/05/2021 | Q2 2021 | -$0.26 | -$0.30 | -0.04 | $16.96 M | $16.29 M |
| 05/06/2021 | Q1 2021 | -$0.29 | -$0.26 | 0.03 | $15.97 M | |
| 02/24/2021 | Q4 2020 | -$0.35 | -$0.32 | 0.03 | $16.37 M | |
| 11/05/2020 | Q3 2020 | -$0.36 | -$0.32 | 0.04 | $17.14 M | $17.79 M |
| 08/06/2020 | Q2 2020 | $0.34 | -$0.34 | -0.68 | $52.99 M | $16.61 M |
| 05/07/2020 | Q1 2020 | -$0.46 | $0.27 | 0.73 | $49.59 M | |
| 02/27/2020 | Q4 2019 | -$0.55 | -$0.78 | -0.23 | $8.28 M |
CytomX Therapeutics, Inc. Earnings: FAQ's
When is CytomX Therapeutics, Inc.'s earnings date?
CytomX Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based off last year's report dates.
Did CytomX Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, CytomX Therapeutics, Inc. (:CTMX) reported $0.07 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.17 by $0.24.
How can I listen to CytomX Therapeutics, Inc.'s earnings conference
call?
The conference call for CytomX Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read CytomX Therapeutics, Inc.'s conference call transcript?
The conference call transcript for CytomX Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does CytomX Therapeutics, Inc. generate each year?
CytomX Therapeutics, Inc. (:CTMX) has a recorded annual revenue of $101.21 M.
How much profit does CytomX Therapeutics, Inc. generate each year?
CytomX Therapeutics, Inc. (:CTMX) has a recorded net income of $101.21 M. CytomX Therapeutics, Inc. has generated $-0.0077 earnings per share over the last four quarters.
What is CytomX Therapeutics, Inc.'s price-to-earnings ratio?
CytomX Therapeutics, Inc. (:CTMX) has a price-to-earnings ratio of 6.58 and price/earnings-to-growth ratio is 0.31.